Thomas Hofmann

Thomas Hofmann is the MannKind as Chief Scientific Officer since December 2020 when MannKind acquired Qrumpharma – a pharmaceutical company with focus on mycobacterial pulmonary disease that Thomas founded. He has spent more than 25 years as a clinical developer of inhaled therapies for lung diseases and is an international leader in the study and treatment of pulmonary diseases such as Cystic Fibrosis, Asthma and COPD. At MannKind, Thomas is focused on leveraging its cutting-edge technology to bring new therapies to patients with orphan lung diseases.